Related Experiment Video
Updated: May 23, 2026
10:13
Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
Published on: December 2, 2022
Topoisomerase 1 inhibitors and cancer therapy
Julia Moukharskaya1, Claire Verschraegen
1Department of Medicine, Vermont Cancer Center, 89 Beaumont Avenue, Given 214, Burlington, VT 05405, USA.
Hematology/Oncology Clinics of North America
|April 24, 2012
Abstract:
Topoisomerase 1 inhibitors cure human cancer xenografts in animal models, more so than most other chemotherapy agents. However, their activity in patients with cancer is modest. Ongoing research is studying the optimal analogues that could reproduce animal data in the cancer population. This article analyzes the clinical research with topoisomerase 1 inhibitors in ovarian cancer.
Insights
Topoisomerase 1 inhibitors show promise in animal cancer models but have modest effects in human patients. Research is ongoing to develop better analogues for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Cancer Therapeutics
Background:
- Topoisomerase 1 inhibitors demonstrate significant efficacy in preclinical cancer models, outperforming many conventional chemotherapy agents.
- Clinical activity of topoisomerase 1 inhibitors in cancer patients has been modest, indicating a gap between animal data and human response.
- Optimizing analogues is crucial to translate the potent preclinical activity of topoisomerase 1 inhibitors into effective patient treatments.
Purpose of the Study:
- To analyze the clinical research landscape of topoisomerase 1 inhibitors specifically within the context of ovarian cancer treatment.
- To evaluate the current status and future directions of topoisomerase 1 inhibitor development for ovarian cancer.
Main Methods:
- Review and analysis of published clinical trials and research studies involving topoisomerase 1 inhibitors in ovarian cancer.
- Examination of data regarding efficacy, toxicity, and patient outcomes in clinical settings.
Main Results:
- Clinical data indicates limited, albeit present, activity of current topoisomerase 1 inhibitors in ovarian cancer patients.
- Variability in patient response suggests the need for further investigation into predictive biomarkers and optimal dosing strategies.
- Ongoing development focuses on novel analogues designed to enhance efficacy and overcome resistance mechanisms observed in ovarian cancer.
Conclusions:
- Topoisomerase 1 inhibitors represent a potential therapeutic avenue for ovarian cancer, but their clinical impact requires enhancement.
- Further research into analogue development and personalized treatment approaches is essential to realize the full therapeutic potential of these agents in ovarian cancer.
- Translating the success seen in animal models to improved patient outcomes remains a key challenge in ovarian cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:02DNA Topoisomerases
Topoisomerases are enzymes that relax overwound DNA molecules during various cell processes, including DNA replication and transcription. These enzymes regulate positive and negative DNA supercoiling without changing the nucleotide sequence. DNA overwinding in a clockwise direction results in positively supercoiled DNA, whereas underwinding in a counterclockwise direction produces negatively supercoiled DNA.
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...